Gadgetine

Replicel Is On Fire Lately — Data In Feb.

br1

br1

Senior Member
Reaction score
2,161
champpy said:
Haha she both. Really f*****g smart but just really ignorant thst there's not much we can honestly do. She told me her friend's boyfriend was using minoxidil and I should try:rolleyes:
Click to expand...
Im my opinion (based mostly on personal experience) one should not expose his own baldness issue.

It's just just something you'll never get any positive outcome. No matter who you share it with..
 
Pephair

Pephair

Established Member
My Regimen
Reaction score
273
People started getting upset regarding how much content he posted and it's importance. He went through a lot of time and effort to make it happen but there was a lot that could of been improved (posting 30 minute videos that were hard to hear, no context, no bullet points, just a clip with sound only and who's speaking). Also missing some important interviews in order to go to every single presentation, even though some of the presentations weren't nearly as important as the potential interviews.

Anyways, I appreciated the effort. But I'm assuming he's gone because he felt attacked.
 
R

razzmatazz91

Senior Member
My Regimen
Reaction score
850
br1 said:
Replicel's stock value has increased 38% in the last month.

At ~.55 cents now, but still...
Click to expand...

f*** me. Was wondering whether to buy it or not a few months ago. It really was oversold.
But, I hope this is a good sign since investments are probably pouring in.

champpy said:
Ive got one better for you.
When i told my girlfriend i was losing my hair her response was simply "well, JUST dont be bald."
Like i have a choice!!
You can slap her for if you want to.
Click to expand...

Don't mind if I do
 
R

razzmatazz91

Senior Member
My Regimen
Reaction score
850
Pephair said:
People started getting upset regarding how much content he posted and it's importance. He went through a lot of time and effort to make it happen but there was a lot that could of been improved (posting 30 minute videos that were hard to hear, no context, no bullet points, just a clip with sound only and who's speaking). Also missing some important interviews in order to go to every single presentation, even though some of the presentations weren't nearly as important as the potential interviews.

Anyways, I appreciated the effort. But I'm assuming he's gone because he felt attacked.
Click to expand...

Sure, there was room for improvement. But I greatly appreciate his efforts.
Has he really stopped posting? Someone give the guy some flowers and tell him we want him back.
 
  • Like
Reactions: br1
T

That Guy

Banned
My Regimen
Reaction score
5,361
champpy said:
Ive got one better for you.
When i told my girlfriend i was losing my hair her response was simply "well, JUST dont be bald."
Like i have a choice!!
You can slap her for if you want to.
Click to expand...

My friend was telling me the other day that his 4 year old niece noticed his hairloss (he's early NW2)

She was like, "Uncle why don't you have hair there?"

He said "Because I'm going bald."

and she was apparently f*****g horrified and said "Why!? Why are you doing that, Uncle? You should stop doing that!"

Rekt by a 4 year old over NW2, god damn.
 
R

razzmatazz91

Senior Member
My Regimen
Reaction score
850
That Guy said:
My friend was telling me the other day that his 4 year old niece noticed his hairloss (he's early NW2)

She was like, "Uncle why don't you have hair there?"

He said "Because I'm going bald."

and she was apparently f*****g horrified and said "Why!? Why are you doing that, Uncle? You should stop doing that!"

Rekt by a 4 year old over NW2, god damn.
Click to expand...
Sounds familiar. I've heard something like that before
 
R

razzmatazz91

Senior Member
My Regimen
Reaction score
850
br1 said:
Replicel's stock value has increased 38% in the last month.

At ~.55 cents now, but still...
Click to expand...

Here's the reason: http://markets.businessinsider.com/...ent-for-Key-Investment-Partnership-1013108216

They've got investment from a Chinese Company called YOFOTO. Now it seems that their treatments other than RCH 01 will undergo trials with this Company.

If they've got traetments that have a real chance of working, then buying this stock at this price might do wonders for us in the long term.
Anyone game for doing some fundamental analysis of Replicel? @JeanLucBB
 
R

razzmatazz91

Senior Member
My Regimen
Reaction score
850
dermrafok said:
Is that good or bad?
Click to expand...
For the company, it's great. It means that giant corporates in the east have faith in their treatments and are purchasing licenses to do trials and exploit the tech commercially.

I don't think it has any bearing on their hair loss cure RCH 01. So for us, it's neither good nor bad.
 
J

Janks16

Established Member
My Regimen
Reaction score
330
Shareholder update for Replicel from January 25, 2018

RepliCel CEO Provides 2018 Shareholder Update



With a new Asian partnership and 2017 deliverables met, RepliCel is primed and ready for expansion

VANCOUVER, BC, CANADA – 25 January 2018 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:p6P2) (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to provide an update to shareholders from its President and CEO, Mr. R. Lee Buckler.

Dear Shareholders,

I am very pleased to be providing this 2018 update. The Company had a very successful 2017, which has only paved the way for a successful year as we enter into 2018. We are ramping up for expansion of all our programs and are actively focused on additional partnership discussions to drive the Company towards maturation. These are exciting times and we look forward to sharing more news as RepliCel continues to gain momentum taking its place as a biotech industry leader.

Looking back over the past 24 months, 2016 was about restructuring and refinancing the Company, 2017 was about delivering promised clinical and injector milestones, and now 2018 is about expansion.

With the rebuilding that the Company has accomplished in the past 24 months, RepliCel has now set the stage to execute across multiple fronts over the next 24 months. Armed with clinical data, functioning device prototypes, a new partner committed to financing our programs in Greater China, and significant capital to execute our programs elsewhere through 2019, we have now positioned RepliCel to deliver on its next phase across several platforms at a faster pace.

We have ongoing research programs at the University of British Columbia in Vancouver, the Shiseido-funded clinical research in Japan, and our dermal injector development taking place in Europe. Expanding from there, we are laying plans for development programs with lead experts in North America and Europe, phase 2 clinical trials in Europe, new clinical trials in Hong Kong and mainland China, regulatory clarity with the United States FDA, and exploring other deals currently under discussion.

In 2018, shareholders should expect to see:

  • The launch of a European multi-centre, phase 2 clinical trial measuring the impact of RCS-01 injections on aging skin.
  • Completion of commercial-grade prototypes for the RCI-02 dermal injector.
  • Filing of a CE-mark application for our dermal injector seeking the regulatory marketing approval needed to commercially launch the device in Europe and Hong Kong.
  • Preparations for launching the device in Hong Kong by licensing partner, YOFOTO (China) Health Industry Co. Ltd.
  • Data from the clinical research being funded by Shiseido in Japan measuring the benefit of RCH-01 injections in men and women suffering from hair loss due to androgenic alopecia.
  • Data from the research program at UBC identifying different genetic marker expression profiles of various cell populations in the hair follicle with an aim of potentially improving cell selection, manufacturing, and clinical outcomes.
  • The launch of tendon repair (RCT-01) and skin rejuvenation (RCS-01) clinical trial activity in Hong Kong and/or Mainland China funded by YOFOTO.
  • The launch of planned product development projects with various partners intended to add significant value to our programs.
  • A meeting with the FDA reviewing one or more of our programs.
  • Business development activity which may well lead to the execution of other commercial partnerships.
Unlike previous years, not only are we are financed to move through these milestones, we have new, significant non-dilutive funding commitments for much of this expansion, subject to successful closing of the deal with YOFOTO.

The pending investment from and partnership with YOFOTO, announced earlier this month, brings to RepliCel a new major shareholder committed not only to finance the programs licensed for Greater China but also to the overall success of the Company. The dilutive investment upfront will be used to fund our programs outside of Asia. This will be counterbalanced with YOFOTO’s funding of our programs in Greater China which will bring significant value to the Company as they generate clinical data and commercialize products. RepliCel shareholders can also look forward to the Company receiving further non-dilutive milestone and royalty payments as part of the YOFOTO partnership.

With the YOFOTO partnership including the dermal injector, we now have a commercial partner able to launch the device commercially in Hong Kong once we have obtained CE-mark approval. This means we now have commercial partnerships in place not only with the potential for near-term commercial launch of RCH-01 in Japan but also a near-term launch of the injector of the device in Hong Kong.

As I outlined in our September press release, we have leveraged our progress in 2017 into a very exciting pipeline of ongoing partnership discussions. While we have now announced the YOFOTO partnership focused on product development and commercialization in Greater China, we have other deals we are in a position to consider in the months ahead. These potential partnerships offer unique opportunities to position and capitalize the Company on its path to increasing maturity.
 
Pephair

Pephair

Established Member
My Regimen
Reaction score
273
This is the data I'm assuming we will be getting regarding the benefit of RCH-01 injections:

RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RepliCel’s proposed Phase 2 trial will enroll 160 male subjects in good health with mild to moderate androgenetic alopecia. Dermal sheath cup cells will be isolated from a small punch biopsy taken from the back of the subject’s scalp. These cells will be replicated and then reintroduced into balding areas on the subjects scalp. After injections are performed subjects will return to the clinic for assessment of total, terminal and vellus hair density and cumulative hair thickness, as well safety. Participants will remain in the trial for approximately 39 months.


This is from their site:
https://replicel.com/product-pipeline/rch-01-hair-regeneration/
 
MrV88

MrV88

Senior Member
My Regimen
Reaction score
1,242
Pephair said:
This is the data I'm assuming we will be getting regarding the benefit of RCH-01 injections:

RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RepliCel’s proposed Phase 2 trial will enroll 160 male subjects in good health with mild to moderate androgenetic alopecia. Dermal sheath cup cells will be isolated from a small punch biopsy taken from the back of the subject’s scalp. These cells will be replicated and then reintroduced into balding areas on the subjects scalp. After injections are performed subjects will return to the clinic for assessment of total, terminal and vellus hair density and cumulative hair thickness, as well safety. Participants will remain in the trial for approximately 39 months.


This is from their site:
https://replicel.com/product-pipeline/rch-01-hair-regeneration/
Click to expand...
Replicel's or Shiseidos? Replicel ain't starting something in the near future.
 
J

Junior2491

Member
My Regimen
Reaction score
42
Wait I thought the phase 2 trials would be read out in Q2 or Q3 of 2018. Possibly launching in Japan late this year. Is that still the case?
 
You must log in or register to reply here.
Community platform by XenForo® © 2010-2023 XenForo Ltd.
Top